Insulin in blister packs shown next to an inhalation device, which is offered by pharmaceutical comapny Pfizer under the name 'Exubera', in Frankfurt Main, Germany, Monday, 20 November 2006. The medicine consists
Inhaled Insulin and Afrezza: What You Should Know
Insulin Flop Costs Pfizer $2.8 Billion - WSJ
Future of Afrezza Inhaled Insulin: Interview with Michael Castagna, CCO of MannKind Corp. | Medgadget
All About Inhaled Insulin
Pfizer Warns of Lung Cancer Risk With Inhaled Insulin
Inhaled insulin: a clinical perspective with emphasis on EXUBERA
Weak Sales Prompt Pfizer to Cancel Diabetes Drug - The New York Times
FDA Panel Says Yes to Inhaled Insulin Device | MedPage Today
Is Inhaled Insulin A Viable Alternative For Patients With Diabetes?
Pfizer dumps Exubera | Nature Biotechnology
Exubera® insulin inhaler with insulin blisters and the inhaler's... | Download Scientific Diagram
Waiting to Inhale
All About Inhaled Insulin
Inhaled Insulin: Into Thin Air?
Left and center: Exubera inhaled insulin delivery system. (Courtesy of... | Download Scientific Diagram
Inhaled, Dry Powder Insulin
Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera - ScienceDirect
Look Ma! No Bong! Afrezza Inhaled Insulin Device is a Cool Gadget - Pharma Marketing Network
Exubera hi-res stock photography and images - Alamy
MannKind's inhaled insulin drug proves hard for diabetics to get - Los Angeles Times
A Sweet Start For Inhalable Insulin
Exubera' insulin inhaler, United States, 2002-2007 | Science Museum Group Collection
Inhaled Insulin Clears Hurdle Toward F.D.A. Approval - The New York Times
Pfizer's inhalable insulin a first for diabetics | Healthcare Packaging
Inhaled Insulin and Afrezza: What You Should Know
Inhaled Human Insulin and its Place in Therapy - ppt video online download
